HighTower Advisors LLC Takes $147,000 Position in Greenwich LifeSciences, Inc. $GLSI

HighTower Advisors LLC acquired a new stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 15,407 shares of the company’s stock, valued at approximately $147,000. HighTower Advisors LLC owned approximately 0.12% of Greenwich LifeSciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GLSI. Wells Fargo & Company MN lifted its holdings in Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after purchasing an additional 1,008 shares in the last quarter. Bank of America Corp DE lifted its holdings in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Rhumbline Advisers lifted its holdings in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. Barclays PLC lifted its holdings in Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after purchasing an additional 1,088 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new position in Greenwich LifeSciences during the first quarter valued at $126,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Noble Financial started coverage on shares of Greenwich LifeSciences in a report on Wednesday, August 20th. They set an “outperform” rating and a $45.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Greenwich LifeSciences has an average rating of “Buy” and a consensus target price of $42.00.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $10.97 on Friday. The stock’s fifty day moving average is $11.26 and its two-hundred day moving average is $10.54. The firm has a market capitalization of $149.52 million, a P/E ratio of -8.07 and a beta of 1.66. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $16.50.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). As a group, sell-side analysts forecast that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.